Skip Navigation


European Heart Journal Advance Access originally published online on March 11, 2005
European Heart Journal 2005 26(9):853-855; doi:10.1093/eurheartj/ehi218
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/9/853    most recent
ehi218v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nicholls, S. J.
Right arrow Articles by Nissen, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicholls, S. J.
Right arrow Articles by Nissen, S. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Strategies to promote HDL-C: an emerging therapeutic target

Stephen J. Nicholls and Steven E. Nissen*

The Cleveland Clinic Foundation, Department of Cardiovascular Medicine/F15, 9500 Euclid Avenue, Cleveland OH 44195, USA

* Corresponding author. Tel: +1 216 445 6852; fax: +1 216 445 5497. E-mail address: nissens@ccf.org

This editorial refers to ‘High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial’{dagger} by A.G. Olsson et al., on page 890

The first 10% of the full text of this article appears below.

Hydroxy-methyl glutaryl coenzyme A reductase inhibitors (statins) have accumulated an extraordinary record of successful randomized clinical trials, transforming the practice of preventive cardiology. However, most placebo-controlled statin trials have reported not more than 25–35% reduction in morbidity/mortality during 5 year follow-up. Thus, despite their established benefits in primary and secondary prevention, statin drugs fail to prevent the majority of clinical events. In acute coronary syndromes (ACS), despite aggressive use of statins, the prognosis is even less favourable. In a recent trial of lipid lowering in ACS, the 2 year event rate was still 22% in the most aggressively treated patients.1 These findings highlight the need to develop new strategies to compliment statins in reducing cardiovascular risk. Emerging therapeutic targets include C-reactive protein, recently shown to have a strong link to outcomes during statin administration.2 However, few therapies other than statins . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial
Anders G. Olsson, Gregory G. Schwartz, Michael Szarek, William J. Sasiela, Michael D. Ezekowitz, Peter Ganz, Michael F. Oliver, David Waters, and Andreas Zeiher
EHJ 2005 26: 890-896. [Abstract] [FREE Full Text]